Published in Hepatology on November 01, 2008
Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS One (2012) 1.15
Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes (2013) 1.10
The relation between dietary fructose, dietary fat and leptin responsiveness in rats. Physiol Behav (2011) 0.93
Way back for fructose and liver metabolism: bench side to molecular insights. World J Gastroenterol (2012) 0.87
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.84
Fructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues. Sci Rep (2016) 0.82
Quercetin Preserves β -Cell Mass and Function in Fructose-Induced Hyperinsulinemia through Modulating Pancreatic Akt/FoxO1 Activation. Evid Based Complement Alternat Med (2013) 0.82
Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight. Nutrients (2014) 0.82
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism (2016) 0.77
AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease. Mol Ther Methods Clin Dev (2014) 0.76
Opposite fates of fructose in the development of metabolic syndrome. World J Gastroenterol (2012) 0.76
Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus. PLoS One (2012) 0.76
TYPE OF SUPPLEMENTED SIMPLE SUGAR, NOT MERELY CALORIE INTAKE, DETERMINES ADVERSE EFFECTS ON METABOLISM AND AORTIC FUNCTION IN FEMALE RATS. Am J Physiol Heart Circ Physiol (2016) 0.75
High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients (2017) 0.75
A Novel Wistar Rat Model of Obesity-Related Nonalcoholic Fatty Liver Disease Induced by Sucrose-Rich Diet. J Diabetes Res (2015) 0.75
Carbohydrate intake as a risk factor for biliary sludge and stones during pregnancy. J Clin Gastroenterol (2013) 0.75
PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol (2012) 2.17
Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med (2004) 2.00
Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. J Biol Chem (2008) 1.95
Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res (2005) 1.95
The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res (2010) 1.89
The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology (2011) 1.72
Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology (2005) 1.42
Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology (2007) 1.40
Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/2 and nuclear factor-kappaB activation. Diabetes (2006) 1.32
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun (2004) 1.20
Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology (2005) 1.15
TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res (2008) 1.15
An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol (2013) 1.13
Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther (2002) 1.13
Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem (2005) 1.11
Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. Curr Mol Pharmacol (2009) 1.02
Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta (2005) 1.01
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol (2010) 1.00
Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells. Endocrinology (2010) 0.98
Increased reactive oxygen species production down-regulates peroxisome proliferator-activated alpha pathway in C2C12 skeletal muscle cells. J Biol Chem (2002) 0.98
Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. J Nutr Biochem (2010) 0.96
Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. Br J Pharmacol (2005) 0.95
Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol (2003) 0.94
Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology (2009) 0.94
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids (2002) 0.94
Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha. Biochem Pharmacol (2004) 0.93
PGC-1α induces mitochondrial and myokine transcriptional programs and lipid droplet and glycogen accumulation in cultured human skeletal muscle cells. PLoS One (2012) 0.93
PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim Biophys Acta (2010) 0.93
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res (2004) 0.93
The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochem Pharmacol (2010) 0.93
Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes (2011) 0.92
Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res (2005) 0.91
Preclinical coronary atherosclerosis in a population with low incidence of myocardial infarction: cross sectional autopsy study. BMJ (2003) 0.90
Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology (2009) 0.90
Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone. J Lipid Res (2003) 0.90
Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc Drug Rev (2003) 0.90
PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia (2014) 0.90
Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochim Biophys Acta (2005) 0.88
Way back for fructose and liver metabolism: bench side to molecular insights. World J Gastroenterol (2012) 0.87
TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes. Biochim Biophys Acta (2012) 0.87
Fructose during pregnancy affects maternal and fetal leptin signaling. J Nutr Biochem (2013) 0.87
Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism (2003) 0.86
Down-regulation of acyl-CoA oxidase gene expression in heart of troglitazone-treated mice through a mechanism involving chicken ovalbumin upstream promoter transcription factor II. Mol Pharmacol (2003) 0.86
Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice. Biochem Pharmacol (2005) 0.86
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages. Eur J Pharmacol (2002) 0.84
Peroxisome proliferator-activated receptor alpha down-regulation is associated with enhanced ceramide levels in age-associated cardiac hypertrophy. J Gerontol A Biol Sci Med Sci (2007) 0.84
Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim Biophys Acta (2011) 0.84
PGC-1beta down-regulation is associated with reduced ERRalpha activity and MCAD expression in skeletal muscle of senescence-accelerated mice. J Gerontol A Biol Sci Med Sci (2006) 0.84
Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol (2006) 0.83
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus. Expert Opin Ther Targets (2012) 0.83
Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. Pharmacogenomics (2008) 0.83
The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells. PLoS One (2011) 0.83
Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages. Mol Cell Biochem (2005) 0.82
Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim Biophys Acta (2011) 0.82
Prevention of age-related changes in rat cortex transcription factor activator protein-1 by hypolipidemic drugs. Biochem Pharmacol (2004) 0.81
Peroxisome proliferator-activated receptors and the control of fatty acid oxidation in cardiac hypertrophy. Mini Rev Med Chem (2006) 0.80
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem Pharmacol (2004) 0.79
Resveratrol induces nuclear factor-κB activity in human cardiac cells. Int J Cardiol (2012) 0.79
Agonist-induced activation releases peroxisome proliferator-activated receptor beta/delta from its inhibition by palmitate-induced nuclear factor-kappaB in skeletal muscle cells. Biochim Biophys Acta (2005) 0.79
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochim Biophys Acta (2013) 0.78
The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease. PPAR Res (2010) 0.78
Gemfibrozil increases the specific binding of rat-cortex nuclear extracts to a PPRE probe. Life Sci (2003) 0.78
Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages. Pharmacogenomics (2012) 0.78
Hypertriglyceridemia and hepatic steatosis in senescence-accelerated mouse associate to changes in lipid-related gene expression. J Gerontol A Biol Sci Med Sci (2007) 0.78
Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli. Biochim Biophys Acta (2007) 0.78
Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration. Exp Gerontol (2005) 0.78